SCHEMBL1068618

SCHEMBL1068618

N#Cc1ccc(CN2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.67
TSHR P16473 2/20 0.59
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP3A4 P08684 3/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPK1 P28482 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CYP2D6 P10635 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
USP2 O75604 2/20 0.54
LMNA P02545 1/20 0.51
CCR2 P41597 1/20 0.51
DPP4 P27487 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
MAPT P10636 1/20 0.50
KCNJ1 P48048 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232757 0.87 FAAH (0.55) FAAHTSHRCYP1A2CYP2C9CYP3A4
SCHEMBL20804360 0.85 KCNJ1 (0.66) FAAHTSHRKMT2AMEN1CYP1A2
SCHEMBL28024576 0.85 KCNJ1 (0.66) FAAHTSHRKMT2AMEN1CYP1A2
SCHEMBL20577290 0.84 HRH3 (0.50) FAAHTSHRKMT2AMEN1ALDH1A1
SCHEMBL7665146 0.83 FNTA (0.73)
SCHEMBL13582762 0.82 FAAH (0.50) FAAHTSHRKMT2AMEN1CYP1A2
SCHEMBL13582765 0.82 FAAH (0.50) FAAHTSHRKMT2AMEN1CYP1A2
SCHEMBL2926678 0.82 FAAH (0.72) FAAHTSHRKMT2AMEN1ALDH1A1
SCHEMBL13149337 0.81 ALDH1A1 (0.70) FAAHTSHRKMT2AMEN1ALDH1A1
SCHEMBL7502026 0.81 CNR1 (0.58) FAAHALDH1A1SMN1; SMN2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104302358-B The assimilation compound of isoquinolin 1 and their therapeutical uses of 3 aryl 5 substitution 癌症研究协会:皇家癌症医院 2017-12-05 CN disclosed
CN-104302358-A 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use CANCER RES INST ROYAL 2015-01-21 CN disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 FAAH 2412/4885TSHR 3869/4885KMT2A 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.